• About Us
    • The founding and management team
    • Advisory Board
    • Scientific Advisiors
    • Selected publications of the management team
  • Technology
    • Targeted protein degradation
    • Exploring degrader targets and degrader chemistries
    • Our technology
  • Career
  • News
Kundenname

Unlock the therapeutic potential of degrader molecules with deep proteomic screening

NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.

Operating at the forefront of innovation within Munich’s biotech hub, we use cutting-edge mass spectrometry technologies to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Our integrated target discovery engine accesses this unprecedented molecular landscape to connect innovative degrader chemistries with the previously undruggable proteome. Systematically extracted neosubstrate candidates are then validated as degrader targets by, for example, ubiquitination analysis to an unparalleled depth of 50,000 sites. Every connection is a new entry point for drug discovery, feeding broad pipelines of first-in-class therapeutics against novel, high-value targets.

Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

Examine
libraries of

> 20.000
compounds

Routinely test degrader
candidates against

> 10.000
proteins

in high throughput
Discover and validate

neosubstrates of degrader drugs

in unprecedented numbers
Build broad drug
discovery pipelines of

novel, high-value
targets

© NEOsphere Biotechnologies GmbH
All rights reserved

Service links
Imprint
Data Policy

Contact
NEOsphere Biotechnologies GmbH
Fraunhoferstrasse 8
82152 Planegg
Germany

Phone: +49 89 4378 020 0
Mail: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

NeoSphere @ LinkedIn